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Abstract
Background: The poor prognosis of advanced HCC and limited efficacy of current systemic treatments emphasize
the need for new or combined targeted therapies. The development of HCC is a multistage process in which liver
injury appears in a complex microenvironment associated with oxidative stress. NOX enzymes are the main source
of ROS during hepatocarcinogenesis and NOX1 in particular has shown correlation with poor prognosis of HCC
patients. This study evaluates the effect of pharmacological NOX1 inhibition on the development and progression
of HCC and its effect on the tumor microenvironment.
Methods: The in vitro cytotoxic effects of the NOX1 inhibitor GKT771 (Genkyotex) on human Huh7 and Hep3B and
murine Hepa1-6 HCC cell lines, the human THP1 monocyte cell line and mouse macrophages were evaluated via
MTT, LDH activity and CaspGlo® assays. In order to induce in vivo HCC, male SV129 wild-type mice received weekly
IP injections of diethylnitrosamine (DEN) (35 mg/kg) for 20–25 weeks. Mice were treated with vehicle or GKT771
(30 mg/kg) via oral gavage, daily or twice daily, in preventive and therapeutic studies. The liver damage was
evaluated for inflammation, angiogenesis, fibrosis and HCC development via histology, RT-qPCR, multiplex analyses
and ROS levels.
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Results: A concentration-dependent reduction in cellular activity of the human HCC cell lines without cytotoxicity
was observed. GKT771 treatment reduced LPS-induced pro-inflammatory bone-marrow derived macrophage
polarization. DEN injections resulted in 100 % tumor formation and the induction of HCC markers which could be
reduced by twice daily dosing of GKT771 at early onset of advanced HCC. DEN-induced HCC resulted in an
upregulation of pro-inflammatory, angiogenic and fibrotic markers which was less pronounced in GKT771 treated
mice in all treatment regimens. In line, liver fibrosis was induced in HCC mice and this to a lesser extend upon
GKT771 treatment.
Conclusions: NOX1 inhibition showed to be safe and well tolerated and was able to attenuate the induction of a
pro-inflammatory, angiogenic and pro-fibrotic microenvironment suggesting that this might be a promising
adjuvant therapeutic strategy in the treatment of advanced HCC.
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Background
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer and represents a major global
health problem with increasing incidence and significant
cancer-related morbidity and mortality. To date, only a
limited number of patients is eligible for curative treat-
ment options, and current therapies for advanced stage
HCC have limited efficacy with significant side effects.
Consequently, there is an urgent medical need for add-
itional systemic therapeutic options [1].
The development and progression of HCC is a multi-
stage process in which a chronic insult (e.g. alcohol
abuse, viral hepatitis, obesity, cholestatic liver injury) in-
duces liver injury characterized by a micro-environment
abundant of various types of cellular stress, including
endoplasmic reticulum stress, cellular DNA damage, ne-
crosis of damaged hepatocytes, and oxidative stress with
reactive oxygen species (ROS) production. In the liver,
ROS are generated in response to a wide variety of en-
dogenous and exogenous stimuli [2–6]. ROS species play
multiple biological roles and are therefore involved in a
large number of physiological phenomena, such as host
defense, but also posttranslational protein processing,
cellular signalling, regulation of gene expression, and
cellular differentiation [7–9]. Their production is
strongly regulated to avoid the harmful effects of a redox
imbalance. In a healthy liver, antioxidant systems such
as superoxide dismutase and catalase efficiently remove
excess of ROS to ensure cellular homeostasis. In con-
trast, during chronic liver disease, increased ROS pro-
duction, as well as decreased activity of the antioxidant
systems, result in oxidative stress [10, 11]. Hepatic car-
cinogenesis is believed to involve ROS-induced DNA
damage and/or mitogenic signalling. Liver injury-
mediated ROS production has been shown to contribute
to mutagenesis and genomic instability, resulting in the
induction of apoptosis and tissue damage. However,
these mutations may also have the potential to activate
oncogenes and/or inactivate tumor suppressors, thereby
initiating oncogenesis. Thus, chronic liver disease-
mediated persistent hepatocyte death establishes a
microenvironment that favors survival and proliferation
of hepatocytes harboring oncogenic mutations. In
addition, when activated, liver resident Kupffer cells
(KCs) release an ‘oxidative burst’ of superoxide and nu-
merous other products with cytotoxic, pro-inflammatory
and growth-promoting activity, and attract circulating
immune cells to the liver; all contributing to the estab-
lishment of a tumor-promoting microenvironment. ROS
also contribute to cancer development and progression,
by acting as second messengers in disease-driven intra-
cellular signaling pathways controlling cell proliferation,
survival, motility and invasiveness, as well as by control-
ling the reactivity of stromal components that are funda-
mental for cancer development and dissemination,
inflammation, tissue repair, and de novo angiogenesis
[11–18].
A number of mechanisms are involved in ROS pro-
duction. NADPH oxidase (NOX) proteins represent the
major non-mitochondrial source of ROS. In addition,
there is a growing body of evidence demonstrating that
one major effect of inflammation-induced cytokine se-
cretion is the upregulation of ROS-producing NOX iso-
forms. Seven homologues of the cytochrome subunit of
NOX have been described (NOX1-5 and DUOX1-2).
NADPH oxidases, with the exception of NOX5, are mul-
timeric complexes, dissociated when inactive, consisting
of cytosolic factors (p47phox, NOXO1, p67phox,
NOXA1, p40phox, and Rac2) and a redox membrane
core. They share the capacity to transport electrons from
NADPH to oxygen across the plasma membrane, and to
generate superoxide and other downstream ROS. Activa-
tion mechanisms, subcellular localization and tissue dis-
tribution are highly isoform-dependent [7, 8]. Various
isoforms, such as NOX1, NOX2, and NOX4, are dis-
tinctively expressed in specific hepatic cell types, includ-
ing KCs, hepatic stellate cells (HSCs), endothelial cells,
hepatocytes, and infiltrating leukocytes. Genetic and
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pharmacological inhibition of NOX1 has been shown to
reduce inflammation and fibrosis in experimental liver
disease [5, 6]. The dual NOX1/4 inhibitor GKT137831
attenuated liver fibrosis, ROS production and the ex-
pression of several fibrotic, inflammatory and prolifera-
tive genes in different mouse models [19–21]. In a phase
I clinical trial, GKT137831 was found to be safe and well
tolerated [22]. Non-phagocytic NOX1 is constitutively
expressed, although its genetic transcription is upregu-
lated by hypoxia, growth factors, growth-related ago-
nists, inflammatory mediators and pathogen-associated
molecular pattern molecules [8, 23]. Recent research on
human HCC samples showed that high NOX1 levels are
correlated with a poor prognosis [24, 25]. The involve-
ment of NOX1 in cell proliferation, tumor growth, cell
motility, epithelial-mesenchymal transition (EMT) and
matrix metalloproteinase-2 production has been shown
in in vitro studies [13, 14]. NOX1-/- knockout mice and
mice with myeloid NOX1 disruption were reported to
develop fewer and smaller tumors following diethylnitro-
samine (DEN) injection. DEN-injected wild type (WT)
mice that received the NOX-1 inhibitor ML171 also de-
veloped fewer and smaller hepatic tumor nodules, com-
pared to their vehicle-treated counterparts [26]. This
antitumor effect observed in mice treated with a NOX1-
specific inhibitor may open up new avenues for HCC
treatment in humans.
In order to further investigate the role of NOX1 and
its potential as a therapeutic target in the treatment of
HCC, we studied the effect of the NOX1 inhibitor
GKT771 (provided by Genkyotex) in a DEN-induced
HCC mouse model, with specific focus on the inflamma-
tory tumor microenvironment (TME).
Materials and Methods
Nox1 inhibitor - GKT310771
GKT310771 is a potent, selective and specific NOX1 in-
hibitor (Ki = 65 ± 30 nM) with an affinity similar to
diphenyliodonium (DPI; Ki = 70 ± 5 nM) that is an irre-
versible and unspecific flavoprotein inhibitor (Genkyo-
tex, Saint-Julien-en-Genevois, France). GKT310771 is
65-fold less effective against NOX4 (Ki = 4290 ± 437 nM)
and does not inactivate NOX2, NOX3 and NOX5. It is
specific for NADPH oxidases over other flavoenzymes
and exhibits no ROS scavenging or antioxidant activity
according to the absence of affinity for xanthine oxidase
and DPPH (Ki > 100 µM). An extensive in vitro off-
target pharmacological profiling of GKT310771 against
various proteins including ROS-producing and redox-
sensitive enzymes, as well as recognized drug targets
(GPCRs, kinases, ion channels and others) failed to re-
veal significant inhibition of any tested candidate when
used at 10 µM, thereby demonstrating high specificity of
GKT310771 for NOX enzymes.
HCC cell culture
The human Hep3B and murine Hepa1-6 cell line were
purchased from American Type Culture Collection
(ATCC, Molsheim, France). The human Huh-7 cell line
was provided by dr. Francesca Fornari [27]. All cell cul-
turing agents and materials were purchased from Life
Technologies, Ghent, Belgium; unless stated differently.
Cell lines were cultured according to the ATCC guide-
lines, incubated at 37 °C under 5 % CO2 and cultured in
Dulbecco’s Modified Eagle Medium (DMEM; Hep3B
and Hepa1-6) or Roswell Park Memorial Institute-1640
(RPMI-1640; Huh-7), supplemented with 10 % Fetal Bo-
vine Serum (FBS) and 1 % Antibiotic Antimycotic Solu-
tion (AA; containing 10’000 units penicillin, 10 mg
streptomycin and 25 µg amphotericin B per mL). For
subculturing, cells were dissociated using 0.05 % trypsin,
stained with trypan blue, and counted using the LUNA-
FL™ Dual Fluorescence Cell Counter (Logos Biosystems,
Annandale, VA, USA).
Cytotoxicity assays
To determine the concentration-dependent cytotoxicity
of the specific NOX1 inhibitor GKT771 (Genkyotex,
Saint-Julien-en-Genevois, France), the cells were seeded
at a density of 15 × 103 cells per well in 96-well culture
plates, and exposed to various GKT771 concentrations
(1.25–100 µM in 1 % dimethylsulfoxide (DMSO)-
enriched culture medium), or equal volumes of solvent,
DMSO-free medium or positive controls (2 µM stauros-
porin for MTT and 2 % Triton-X for LDH) for 24–48 h.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-difenyltetrazolium
bromide (MTT) assay (Roche Diagnostics, Anderlecht,
Belgium) was used according to the manufacturer’s
protocol to determine the mitochondrial metabolic ac-
tivity, a measure for cellular viability. Briefly, cells were
incubated with 0.5 mg/ml MTT for 2 h at 37 °C. Mito-
chondrial dehydrogenases degrade MTT into insoluble
formazan crystals and the absorbance of these DMSO-
solved crystals was measured at 570 nm against a back-
ground control of 630 nm with a spectrophotometer
(Multiskan Ascent). The results are shown as percent-
ages of the solvent-treated control group.
The supernatant of the treated cells was used to meas-
ure the lactate dehydrogenase (LDH) activity according
to the manufacturer’s protocol (Biovision, Milpitas, Cali-
fornia, USA). The cytosolic enzyme LDH is released into
the culture medium following cytotoxic damage-
mediated plasma membrane disruption. LDH was quan-
tified via a coupled enzymatic reaction in which LDH ca-
talyses lactate to pyruvate through NAD+ reduction. The
released NADH is used by diaphorase to reduce a tetra-
zolium salt into a red formazan product. The absorbance
of the latter was measured at 490 nm against a back-
ground control of 630 nm.
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The luminescent CaspGlo® 3/7 (Promega, Leiden, The
Netherlands) was used to measure caspase-3 and − 7 ac-
tivities of the different adherent cell cultures. Upon cell
lysis, the proluminescent caspase-3/7 substrate, which
contains the tetrapeptide sequence DEVD, is cleaved by
caspase-3/7. This releases aminoluciferin, which in turn
is used by luciferase for the production of light, allowing
quantification of the apoptotic state of the cell cultures.
All cells were incubated in the dark for 2 h with the
CaspGlo® 3/7 reagent prior to detection with a lumin-
ometer (Fluostar, BMG Labtech, De Meern, The
Netherlands).
Mouse BMDM and human monocyte cell line THP1
Murine bone marrow-derived macrophage single cell
isolates were obtained from mice by flushing the femurs
and tibiae with ice-cold phosphate-buffered saline (PBS).
After centrifugation (7 min; 1200 rpm; 4˚C), the pellet
was resuspended in pre-heated (37 °C) DMEM supple-
mented with 20 ng/ml murine macrophage colony-
stimulating factor (M-CSF, PeproTech, London, UK),
50 µg/ml Gentamycin (from 3 mg/ml stock), 10 % FBS
and 1 % AA. Cells were seeded in two 10 cm petri dishes
per mouse, with each containing approximately 20 × 106
primary bone marrow-derived macrophages (BMDMs)
after 7 days of culturing. Medium was refreshed every
other day and cells were collected using enzyme-free dis-
sociation buffer. For the human THP1 monocyte cell
line, cells were cultured in suspension in RPMI-1640
supplemented with 10 % FBS. Prior to treatment with
GKT771, cells were seeded into well-plates and stimu-
lated with 12-O-tetradecanoylphorbol-l3-acetate (PMA,
10 ng/ml) to allow differentiation into macrophages.
Concentration-dependent cytotoxicity of GKT771 with
and without lipopolysaccharide (LPS)-stimulation (1 µg/
ml; Sigma-Aldrich) on mouse and human macrophages
was determined via the MTT and LDH assay, as de-
scribed above.
Mice
All animal experiments were reviewed and approved by
the Animal Ethics Committee of the Faculty for Medi-
cine and Health Sciences, University Ghent (ECD18/50).
Five-week-old male SV129 wild-type mice, purchased
from Janvier Labs (Le Genest-Saint-Isle, France), were
housed at room temperature and constant humidity in a
12-hour controlled dark/light cycle at the animal facility
of the Faculty of Medicine and Health Sciences, Ghent
University, Belgium. Mice received standard chow
(Pavan Service-Carfil, Oud-Turnhout, Belgium) and
water ad libitum before and during the experiment. The
welfare of all animals was evaluated daily and the mice
were weighted weekly, during the entire duration of the
experiment.
Preparation of vehicle and dose formulation
Vehicle consisted of deionized water containing 1.2w%
methylcellulose and 0.1w% Polysorbate 80 (Tween 80),
which was stirred overnight at 4 °C to allow complete
solubilisation. GKT771 was dissolved in vehicle solution.
Both solutions were stored at 4 °C, protected from light
and stirred for at least 10–15 minutes before oral admin-
istration (dosage of 30 mg/kg).
Preventive study
In order to induce HCC, mice received weekly intraperi-
toneal (IP) injections of saline or diethylnitrosamine
(DEN; 35 mg/kg, Sigma-Aldrich, Diegem, Belgium) for
25 weeks. At week 15, mice were randomised into 4
treatment groups and treated for 15 weeks: vehicle-
treated healthy saline controls (n = 6), GKT771-treated
healthy saline controls (n = 4), vehicle-treated DEN-
induced HCC mice (n = 7) and GKT771-treated DEN-
induced HCC mice (n = 10). Mice were treated daily via
oral gavage. At week 30 of the experiment, mice were
sacrificed (Fig. 1a).
Therapeutic study
Two different treatment regimens were applied in the
therapeutic setting of the experimental set-up. As in the
preventive setting, mice received weekly IP injections of
saline or DEN. This was maintained for 25 weeks in the
early treatment regimen and 20 weeks in the delayed
treatment regimen. Since HCC nodules are macroscop-
ically visible as soon as 20 weeks of DEN [28], an early
treatment regimen was started in which mice were
planned to be treated with vehicle (n = 11) or GKT771
(n = 9) twice daily via oral gavage for a total of 10 weeks.
However, due to ethical reasons, early euthanasia was
performed after 9 weeks. A second treatment regimen
was set up in which mice were kept in a resting period
of 2 weeks after the final DEN injection at week 20. Dur-
ing this delayed treatment regimen, mice were treated
daily with vehicle (n = 5) or GKT771 (n = 6) for 5 weeks
via oral gavage (Fig. 1b).
Sample collection
At the day of sacrifice, mice were weighted, and anesthe-
tized by intraperitoneally injecting a ketamine (100 mg/
kg) – xylazine (10 mg/kg) solution for blood sampling.
The mice were euthanized via cervical dislocation prior
to dissection. Both spleen and liver were isolated and
weighed, after which the number of nodules was macro-
scopically evaluated. The lesions of the mice from the
preventive study and of the treatment regimen 2 of the
therapeutic study were manually separated from the
non-tumorous liver tissue. Liver tissue without tumors,
the tumors and the total livers were divided into differ-
ent sections for further analyses. Sections for RNA
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analysis were collected in RNA-later, snap-frozen using li-
quid nitrogen and stored at -80 °C until further analysis.
Tissue sections for histological examination were collected
in cassettes and fixed in a 4 % phosphate-buffered formal-
dehyde solution, and embedded in paraffin.
Total RNA extraction
For the quantification of specific gene transcript levels, nee-
dle homogenisation was performed on all tissue samples
prior to lysis with RLT lysis buffer supplemented with β-
mercaptoethanol (Biorad, Temse, Belgium). Total RNA was
extracted from all samples using the Aurum™ Total RNA
Mini Kit according to the manufacturer’s Spin Format
Guidelines (Biorad, Temse, Belgium). The purity and quan-
tity of total RNA was assessed using spectrophotometry
(Nanodrop, Thermo Scientific, Wilmington, USA). Purity
was determined using the ratio of absorbance at 260 and
280 nm (only ratios between 1.8 and 2.0 were accepted).
Quantitative real‐time polymerase chain reaction
One microgram of total RNA was converted to single
strand cDNA by reverse transcription (Sensifast cDNA
synthesis kit, Bioline Reagents Ltd, Kampenhout,
Belgium), following the cDNA Bio thermocycler pro-
gram (10’ 25 °C, 15’ 42 °C, 5’ 85 °C). The cDNA was di-
luted 1/10 prior to real-time quantification via reverse
transcriptase quantitative real-time polymerase chain re-
action (RT-qPCR) using SYBR Green (NO-ROX, Sensi-
mix, Bioline Reagents Ltd., Waddinxveen, The
Netherlands) according to the manufacturer’s guidelines.
All reactions were performed in duplicate. All used pri-
mer sequences (Biolegio, Nijmegen, The Nederlands) are
listed in Table 1. A real-time cycling program (initial de-
naturation: 10’ 95 °C; 40 PCR cycles: denaturation 10”
95 °C and annealing/extension/fluorescence reading 60”
60 °C) was run on a Lightcycler® 480 II (Roche, Mache-
len, Belgium) and melting curve analysis was performed
to assess primer specificity. The threshold cycle (Ct)
values were further analysed using the 2−ΔΔCT method.
In short, the average of the in duplo Ct values of the
household and target genes were calculated. The geo-
metric mean of these values of the stable household
genes (determined via GeNorm) were calculated and
subtracted from the in duplo averages of the target genes
(= ΔCp). Next, the mean of the ΔCp of the control sam-
ples was subtracted from the ΔCp of each individual
Fig. 1 Timeline of in vivo GKT771 studies in DEN-induced HCC. a In the preventive study, five-week-old male SV129 wild-type received
intraperitoneal injections of saline or 35 mg/kg DEN for 25 weeks to induce HCC. During HCC development (week 15 of DEN), mice were treated
daily with vehicle or GKT771 (30 mg/kg) via oral gavage for 15 weeks. b In the therapeutic studies, mice received weekly DEN injections for 25
weeks or 20 week in the early and delayed treatment regimen, respectively. In the early treatment regimen, mice were treated with GKT771 twice
daily after 20 weeks of DEN for a total of 9 weeks (early euthanasia). Mice in the delayed treatment regimen were kept in a resting period of 2
weeks after the final DEN injection prior to daily GKT771 treatment for 5 weeks
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sample (= ΔΔCp) and the power was calculated (=
2−ΔΔCT). All expression analysis graphs display these
powers, and statistical analysis was performed on the
normalized log10 transformed data of these powers. Stat-
istical analyses were performed as described below.
Luminex
Snap-frozen liver tissue was defrosted in 1 mg/mL pro-
tease inhibitor cocktail (cOmplete™, Mini, EDTA-free
Protease Inhibitor Cocktail, 04693 159 001, Roche,
Sigma-Aldrich, Overijse, Belgium), 1 v% phosphatase in-
hibitor cocktail 2 (P5726, Sigma-Aldrich, Overijse,
Belgium) and 1 v% phosphatase inhibitor cocktail 3
(P0044, Sigma-Aldrich, Overijse, Belgium) in PBS, lysed
by sonication and centrifuged for 15 min by 15,000 rpm
at 4 °C. Supernatant was stored at − 80 °C until further
analysis. Total protein concentrations were measured by
BCA protein assay following manufacturer’s guidelines
(DC protein assay, 500 − 0116, Bio-Rad, Temse,
Belgium). Protein levels of TNF-α, MCP-1/CCL2 and
IL6 were determined by using Bio-plex Pro Reagent Kit
and Luminex microbeads (Biorad, Temse, Belgium) ac-
cording to the manufacturer’s guidelines.
ROS assay
Hepatic tissue lysates were prepared by defrosting snap-
frozen liver tissue in PBS prior to sonication on ice. The
lysates were centrifuged for 5 min by 10,000 g at 4 °C.
The supernatant was used for the quantification of ROS
levels, which was performed using a commercial DCF
ROS/RNS Assay Kit (Ab238535, Abcam, Cambridge,
United Kingdom,) according to the manufacturer’s
instructions.
Histological analysis
After deparaffinization and rehydration of the tissue
samples, sections of 5 µm of paraffin-embedded liver tis-
sue were stained with Sirius Red (Sigma-Aldrich) for
histopathological examination according to the Metavir
Table 1 Primers used for the mRNA expression analyses conducted on the murine BMDM and liver tissue samples
Marker Gene ID Gene name Forward primer Reverse primer
Inflammation CCR2 C-C Motif Chemokine Receptor 2 ATCCACGGCATACTATCAACATC CAAGGCTCACCATCATCGTAG
CCL2 C-C Motif Chemokine Ligand 2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT
IL6 Interleukin 6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
IL1β Interleukin 1 beta CAACCAACAAGTGATATATTCTCC
ATG
GATCCACACTCTCCAGCTGCA
TNFα Tumor Necrosis Factor alpha CATCTTCTAAAATTCGAGTGACAA TGGGAGTAGACAAGGTAC
AACCC
Inflammasome iNOS Inducible Nitric Oxide Synthase GGCAGCCTGTGAGACCTTTG GCATTGGAAGTGAAGCGTTC





Caspase 1 AATACAACCACTCGTACACGTC AGCTCCAACCCTCGGAGAAA
Immune
suppression
PDL1 Programmed death-ligand 1 GACGCAGGCGTTTACTGCT GCGGTATGGGGCATTGACTTT
HCC AFP Alphafetoprotein AGCTTCCACGTTAGATTCCTCC ACAAACTGGGTAAAGGTGATGG
GP3 Glypican 3 TCGACAGCCTCTTTCCCAGTCA GGTCACGTCTTGCTCCTCG
Stemness MDR1 Multidrug Resistance 1 AGCCGTAAGAGGCTGAGGCCG TCACGTGCCACCTCCGGGTT
EPCAM Epithelial Cell Adhesion Molecule GCGGCTCAGAGAGACTGTG CCAAGCATTTAGACGCCAGTTT
CD44 Cluster of Differentiation 44 TCGATTTGAATGTAACCTGCCG CAGTCCGGGAGATACTGTAGC
CD133 Cluster of Differentiation 133 CTCCCATCAGTGGATAGAGAACT ATACCCCCTTTTGACGAGGCT
Angiogenesis CD31 Cluster of Differentiation 31 TGCCTTGTTCATGTTGGGTA CCTCAGAATATTCCAGGGCA
END Endoglin CCACCGGCCATGAACTTGTCCC AGTGGGGTGAGGAGATCC
CAAGG
iCAM Intercellular Adhesion Molecule 1 GCCTTGGTAGAGGTGACTGAG GACCGGAGCTGAAAAGTTGTA
vCAM Vascular Cell Adhesion Protein 1 TGCCGAGCTAAATTACATATTG CCTTGTGGAGGGATGTACAGA
Fibrosis αSMA Alpha-Smooth Muscle Actin CCAGCACCATGAAGATCAAG TGGAAGGTAGACAGCGAAGC
COL1A1 Collagen type 1 alpha GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG
TGFβ Transforming Growth Factor beta TGAGCGTCACTGGAGTTGTACGG GGTTCATGTCATGGATGGTGC
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scoring system. This system allows to assess the extent
of fibrosis in our liver samples, which was visualised
using the Cell^D software (Olympus).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 8 (GraphPad Software, California, USA). Normal-
ity was tested using the D’Agostino & Pearson omnibus
test. Outliers were identified with the ROUT method
and were removed for further analysis. The maximum
desired false discovery rate was set to 1 %. Gaussian dis-
tributed data of two groups were compared via t-tests
and multiple groups were compared by one-way analysis
of variance (ANOVA) test and corrected with the Holm-
Sidak test. Non-normally distributed data were either
transformed to Gaussian distribution via LOG10-trans-
formations or analysed via Kruskal Wallis tests for mul-
tiple comparison. Data are presented as the fold change
relative to expression in controls as mean ± SD, unless
stated differently in the figure legends. P-values are re-
ported two-sided and considered significant when less
than 0.05 (*p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001).
Results
Moderate doses of GKT771 treatment do not induce HCC
cell cytotoxicity in vitro
To assess the potential cytotoxic effects of NOX1 inhib-
ition in vitro, two human HCC cell lines (Huh7 and
Hep3B) were treated for 24 hours with various concentra-
tions of GKT771, ranging from 0 to 100 µM. Mitochon-
drial metabolism was examined as an indicator of cell
viability using the MTT assay, and was found to be signifi-
cantly reduced in a concentration dependent manner in
both cell lines (Fig. 2a & d). No loss of membrane integrity
or increase in caspase 3/7 activity could be detected using
an LDH and CaspGlo® assay respectively, which indicates
the absence of cell lysis or apoptotic cell death of human
HCC cells upon treatment with GKT771 at concentra-
tions up to 100 µM (Fig. 2b-c & e-f).
Identical analyses following a similar GKT771 treat-
ment regimen in the murine Hepa1-6 HCC cell line
Fig. 2 Moderate doses of GKT771 treatment do not induce HCC cell cytotoxicity in vitro. To determine the concentration-dependent cytotoxicity
of specific NOX1 inhibition, human Huh7 a-c and Hep3B d-f and murine Hepa1-6 g-i HCC cells were treated for 24 hours with 1.25–100 µM
GKT771 (NOXi), vehicle (V), vehicle-free medium (M) or positive controls (S and Tx). MTT (mitochondrial metabolism), LDH (membrane integrity,
necrosis) and CaspGlo® (apoptosis) assays were performed. The results are shown as percentages of the vehicle-treated control group. S:
Staurosporin; Tx: Triton-X; M: Vehicle-free medium; V: Vehicle. Data shown as mean ± SD, nsnot significant; *p < 0,05; **p < 0,01; ***p < 0,001; ****p <
0,0001 compared to vehicle, unless indicated differently
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revealed no significant alterations in mitochondrial me-
tabolism and caspase 3/7 activity (Fig. 2g & i). However,
an impaired cellular membrane integrity could be ob-
served at 100 µM, indicating the presence of a moderate
toxic effect at the highest concentration (Fig. 2h).
NOX1 inhibition attenuates LPS-induced macrophage
polarization
Murine bone marrow-derived single cell isolates and
THP1 cells were seeded in medium containing M-CSF
or PMA respectively, to induce proliferation and differ-
entiation into macrophages. The resulting primary
BMDMs and THP1 macrophages were treated with
100 µM of GKT771 with and without LPS-stimulation.
MTT and LDH analyses showed a significant enhance-
ment of the mitochondrial metabolic state associated
with a disruption of cellular membrane integrity of
GKT771-treated BMDMs in both the presence and
absence of LPS (Fig. 3a). In the human monocyte cell
line THP1, GKT771 induced a decrease in cell metabolic
activity and increased cytotoxicity, in both the presence
and absence of LPS (Fig. 3b).
To assess the effect of NOX1 inhibition on the
polarization of BMDMs in vitro, the mRNA expression
of inflammatory markers (CCL2, IL6, IL1β, TNFα, iNOS,
NLRP3 and Caspase 1) and of the immune suppressive
marker PDL1 was examined via RT-qPCR upon treat-
ment of these cells with 100 µM of GKT771, with and
without LPS. LPS activation of the murine BMDMs re-
sulted in a significant increased expression of the ana-
lysed markers which was significantly less pronounced
in combination with NOX1 inhibition for CCL2, IL6,
IL1β, iNOS, NLRP3 and Caspase 1 (Fig. 3c). Our results
were confirmed in the human monocyte cell line THP1
for the inflammatory markers CCL2, IL6, IL1β and
TNFα (Fig. 3d). This shows that NOX1 inhibition is able
Fig. 3 Cytotoxic effects of NOX1 inhibition on mouse BMDMs and human monocyte cell line THP1. Murine bone marrow-derived single cell
isolates and THP1 cells were cultured in medium containing M-CSF or PMA respectively, to induce differentiation into macrophages. The resulting
BMDMs and THP1 cells were treated with vehicle/100 µM of GKT771 for 48 h with and without LPS-stimulation (1 µg/ml). a-b MTT and LDH
analyses were performed to determine the mitochondrial metabolic state and the disruption of cellular membrane integrity respectively. NOX1
inhibition attenuates LPS-induced BMDM polarization. c-d mRNA expression of different inflammatory markers was examined via RT-qPCR. Data
presented as relative expression to vehicle-treated controls in the absence of LPS. nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p <
0,0001 compared to vehicle without LPS, unless indicated differently
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to attenuate LPS-induced polarization in both murine
BMDM and the human monocyte cell line THP1.
NOX1 inhibition attenuates the development of a pro‐
tumorigenic microenvironment during HCC development
Mice received weekly IP injections of DEN for 25 weeks.
At week 15, daily treatment with GKT771 was initiated
to evaluate the effect of NOX1 inhibition on tumor de-
velopment. DEN administration resulted in a mild de-
crease in body weight and a moderately elevated spleen
weight (not significant). As expected, DEN administra-
tion induced macroscopically visible tumoral lesions in
the liver of both vehicle and GKT771 treated mice, while
in the healthy control groups (saline) no lesions were de-
tected. Preventive GKT771 treatment did not signifi-
cantly alter the total number of tumor lesions in the
liver (Fig. 4a-b). In line, the expression of two HCC
markers, AFP and GP3, was induced in tumor and
surrounding liver tissue of both vehicle and GKT771
treated HCC mice (Fig. 4c). However, significant induc-
tion of hepatic cancer stem cell markers (MDR1, EPCA
M, CD44 and CD133) in the tumors and surrounding
liver tissue was attenuated upon GKT771 treatment
(Fig. 4c).
DEN-induced HCC resulted in an induced expression
of inflammatory markers IL6, TNFα, IL1β, CCR2, CCL2,
Caspase 1 and NLRP3, and of the immune suppressive
marker PDL1, compared to healthy control liver tissue
(Fig. 5). This induction was most explicit and significant
in the tumor lesions, but also present in surrounding
liver tissue. Preventive administration of GKT771 re-
sulted in a less pronounced induction of these markers,
both in tumor lesions and surrounding tissue (Fig. 5).
To further evaluate the effect of GKT771 on the pro-
gressing tumoral microenvironment, mRNA expression
analysis of angiogenic and fibrotic markers was
Fig. 4 NOX1 inhibition does not prevent HCC development in mice. In order to induce HCC, mice received weekly DEN (35 mg/kg) injections for
25 weeks. At week 15, mice were treated daily with vehicle or 30 mg/kg of GKT771 for 15 weeks via oral gavage. At week 30 of the experiment,
mice were sacrificed. a Body, liver and spleen weight were recorded and b macroscopically visible tumors were counted. NOX1 inhibition
attenuates the Induction of hepatic cancer stem cell markers in DEN-induced HCC. c The mRNA expression of HCC (AFP and GP3) and cancer
stem cell (MDR1, EPCAM, CD44, CD133) markers in the separated tumoral lesions and non-tumoral surrounding liver tissue of both vehicle and
GKT771 treated HCC mice was evaluated by RT-qPCR. nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-
treated healthy controls, unless indicated differently
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performed. NOX1 inhibition was able to attenuate DEN-
induced induction of both angiogenic (CD31, END,
iCAM, vCAM) and fibrotic (αSMA, COL1A, TGFβ)
markers (Fig. 6a-b). Histological analysis of liver fibrosis
confirmed this anti-fibrotic effect of NOX1 inhibition
early in DEN-induced HCC development (Fig. 6c).
Early treatment and twice daily dosing of the NOX1
inhibitor is able to attenuate the progression of advanced
HCC
To evaluate the therapeutic potential of NOX1 inhib-
ition in advanced HCC, two treatment regimens were
set-up including an early and delayed treatment protocol
(Fig. 1b). In both treatment regimens, DEN administra-
tion induced macroscopically visible tumoral lesions in
the liver, while in the saline-treated control group no le-
sions were detected (Fig. 7a-b). Early treatment and
twice daily dosing of GKT771 during advanced HCC re-
sulted in reduced HCC lesions compared to no treat-
ment (Fig. 7a-b). This was confirmed by less induced
expression of the HCC markers AFP and GP3, both in
the early (twice daily dosing) and delayed (single daily
dosing) treatment group compared to untreated HCC
mice (Fig. 7c). Assessment of the TME of advanced
HCC liver tissue showed induction of markers involved
in inflammation (IL1β, TNFα, IL6, CCL2, CCR2),
inflammasome activation (Caspase 1, NLRP3, iNOS), im-
mune suppression (PDL1), angiogenesis (END, CD31,
iCAM, vCAM) and fibrosis (αSMA, TGFβ, COL1A)
compared to healthy control livers (Figs. 11, 12 and 13A,
light grey bars). In early twice daily dosed treated HCC
mice, a (partial) loss of significant induction of IL1β,
TNFα, CCL2, CCR2, Caspase 1 and NLRP3 in the HCC
lesions could be observed (Fig. 8a). This was also con-
firmed by multiplex analysis showing reduced CCL2,
TNF and IL6 production in NOX1i treated mice. Fur-
thermore, treatment with NOX1 inhibition resulted in
downstream inhibited ROS production in both treat-
ment regimen (Fig. 8b). Expression of angiogenic marker
vCAM was less induced in both the non-cancerous
Fig. 5 NOX1 inhibition dampens the upregulation of pro-inflammatory markers during HCC development. After 25 weeks of DEN administration
and 15 weeks of vehicle/GKT771 treatment, HCC lesions and non-tumoral surrounding liver tissue were sampled for mRNA expression analysis.
The expression of inflammatory markers (IL6, TNFα, IL1β, CCR2, CCL2, Caspase 1 and NLRP3) and of the immune suppressive marker PDL1 was
performed via RT-qPCR. Data shown as mean ± SEM. nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-
treated healthy controls, unless indicated differently
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surrounding liver tissue and the HCC lesions of early
twice daily treated HCC mice (Fig. 9a). Fibrosis was at-
tenuated in both early and delayed GKT771 treated
HCC mice, indicated by a (partial) loss of significant in-
duction of COL1A and TGFβ expression in the sur-
rounding liver, HCC lesions and total liver tissue
(Fig. 9b). Furthermore, both treatment regimens resulted
in a reduced Metavir score compared to untreated HCC
mice (Fig. 9c).
Discussion
HCC related morbidity and mortality continues to rise
as approximately forty percent of HCC patients have ad-
vanced underlying liver disease and are not eligible for
potentially curative treatment options. The poor progno-
sis of advanced HCC is partly due to the limited efficacy
and many adverse events of existing systemic treatments
[1]. Consequently, there is an absolute medical need for
the development and evaluation of new targeted therap-
ies, which could also potentiate the clinical benefits of
current systemic therapies. Our current study evaluated
the effect of chemical NOX1 inhibition on the develop-
ment of HCC and its potential as therapeutic strategy
with focus on interference with the TME.
The development and progression of HCC occurs in
the context of a complex microenvironment associated
with many types of cellular stress. These stress pathways
and their molecular mediators could serve as adequate
candidate targets for such adjuvant systemic treatment
strategies. In particular, due to the massive oxygen con-
sumption in the growing tumor, hypoxia is a prevalent
feature of the hepatic TME. In a hypoxic environment,
persistent ROS accumulation induces inflammatory re-
sponses, resulting in genetic instability, chromosomal
damage, and tumor development and metastasis. These
increased amounts of ROS are generated by non-
mitochondrial sources such as NADPH oxidase (NOX)
enzymes [29]. High NOX1 levels have been shown to
correlate with poor prognosis of HCC patients [24, 25].
Interestingly, in an experimental colon carcinoma model,
treatment with a NOX1 inhibitor (GKT771) in combin-
ation with an anti-PD1 immune checkpoint inhibitor
had an additional inhibitory effect on tumor growth,
which suggest a possible therapeutic capacity of combin-
ing NOX1 inhibitors in other solid tumors such as HCC
[31]. However, studies on this potential benefit of NOX1
inhibition in the prevention or treatment of HCC are
still limited.
We first assessed the potential direct cytotoxic effects
of NOX1 inhibition on human HCC cells by subjecting
Huh7 and Hep3B cells to various concentrations of
GKT771. Our results suggest a reduced cellular activity
of these human HCC cell lines without cytotoxicity.
However, this was not the case in the murine Hepa1-6
cell line, were no concentration-dependent reduction of
cellular activity could be detected and cytotoxicity was
Fig. 6 NOX1 inhibition attenuates the induction of angiogenic and fibrotic markers during HCC development. After 25 weeks of DEN
administration and 15 weeks of vehicle/GKT771 treatment, HCC lesions and non-tumoral surrounding liver tissue were sampled for mRNA
expression analysis. RT-qPCR was performed to determine the expression of a different angiogenic markers (CD31, END, iCAM and vCAM) and
b fibrotic markers (αSMA, COL1A and TGFβ). Data shown as mean ± SEM. nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; ****p < 0,0001
compared to vehicle-treated healthy controls, unless indicated differently. c Sirius red staining of the livers of DEN-induced HCC mice receiving
preventive GTK771 treatment was performed and Metavir scoring was compared to vehicle treated HCC mice. Data shown as individual scoring
points with median. Metavir score: F0 - no fibrosis; F1 - fibrosis exists with expansion of portal zones; F2 - : fibrosis exists with expansion of most
portal zones, and occasional bridging
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induced at the highest GKT771 concentration. These
data suggest a different sensitivity of human and murine
HCC cell lines in in vitro NOX1 inhibition.
We next wanted to investigate the anti-tumoral effect
of NOX1 inhibition in an in vivo setting of orthotopic
HCC in the context of a complex microenvironment.
Therefore, we used a DEN-induced HCC mouse model
to investigate whether chemical NOX1 inhibition is able
to reduce HCC development. While we did not observe
a reduction in HCC lesions in this preventive setting,
NOX1i reduced the induction of tumoral stemness
markers indicating the involvement of NOX1 in tumor
aggressiveness. Liu et al. [29] previously stated that
tumor hypoxia accelerates the aggressiveness of HCC
cells due to the close relationship between ROS on the
one hand, and EMT, tumor progression, invasiveness,
angiogenesis, phenotype conversion and distant metasta-
sis on the other hand. The insufficient oxygen amount
in a hypoxic microenvironment limits tumor cell div-
ision, facilitates transition of malignant cells towards a
more metastatic phenotype and endorses treatment re-
sistance, in which cancer stem cells have been proven to
play an important role. Additionally, high expression of
NOX1 has been associated with HCC progression and
aggressiveness [30].
In order to be able to translate results to a more clin-
ical setting, two treatment regimens of NOX1i were
evaluated in advanced/established HCC. Here, early
treatment with a double daily dose of NOX1i resulted in
an attenuation of HCC progression, which confirms the
results published by Liang et al. showing that NOX1-/-
knockout mice or WT mice given DEN followed by the
NOX-1 inhibitor ML171 developed fewer and smaller
tumors after DEN injection. Additional to the investiga-
tion of cancerous traits of HCC, we focused on the ef-
fects of GKT771 on the tumoral microenvironment
during HCC development. Interestingly, pro-
inflammatory and angiogenic markers were less induced
and fibrosis attenuated upon NOX1 inhibition during
HCC progression in mice. Both our preventive and
Fig. 7 Twice daily dosing of GKT771 at onset of advanced HCC reduces HCC lesions. Mice received weekly DEN (35 mg/kg) injections for 25 or
20 weeks and received twice or single daily doses of vehicle/GKT771 via oral gavage in an early or delayed treatment regimen, respectively.
a Mice were sacrificed and morphometric data (body, liver and spleen weight) was recorded. Data shown as mean ± SD. b Macroscopically visible
tumors were counted and subdivided into three categories (large, intermediate, small). Data shown as mean ± SD. nsnot significant; * p < 0,05; **
p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently. c: mRNA expression of HCC
markers (AFP and GP3) in tumors and non-tumoral surrounding liver tissue of vehicle (light grey bars) and GKT771 treated (dark grey bars) mice
was determined via RT-qPCR. Data shown as mean ± SEM. nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to
vehicle-treated healthy controls, unless indicated differently
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therapeutic studies confirm the ability of NOX1 inhib-
ition to reduce the induction of a pro-inflammatory, an-
giogenic and pro-fibrotic microenvironment. For the
DEN-induced HCC mouse model, it has been shown
that NOX1 knockout mice exhibit equal amounts of
hepatic DNA damage compared to wild type mice. This
suggests that the carcinogenic effect of DEN is not only
induced by DNA damage but in addition, ROS use a dif-
ferent mechanism of action generating hepatocyte injury,
cell death, inflammation, and compensatory proliferation
and fibrosis in the pathogenensis of DEN-induced HCC
[26]. As both preventive and therapeutic GKT771 treat-
ment in DEN-induced HCC attenuate the development
of a pro-tumorigenic, and especially pro-fibrotic, micro-
environment, NOX1 inhibition potentially possesses an
adjuvant value to currently tested and available HCC
therapies. The TME composes a biological barrier
around solid cancers that prevents immunotherapy from
effectively working. The TME is acidic, hypoxic and full
of toxins and acts like a barricade that is able to fend off
or chemically assault cancer-killing immune cells [31].
Furthermore, it has been shown that the TME mediates
the resistance of HCC towards tyrosine kinase inhibitors
such as Sorafenib, via the regulation of cell stemness,
mesenchymal state of tumor cells and epigenetic mecha-
nisms [32].
Different hepatic cell types, including hepatocytes, HSCs
and KCs, express NOX1 [8, 22, 33]. However, Liang et al.
recently published that NOX1 expression in macrophages,
but not in other hepatic cell types, mediates their tumor-
promoting activity [26]. We observed that primary murine
BMDMs treated with GKT771 displayed a significant en-
hanced mitochondrial metabolic state, associated with
plasma membrane disruption, both in the presence and
absence of LPS, suggesting a moderate direct toxic effect
of NOX1 inhibition in these immune cells. Therefore, we
further assessed the effect of NOX1 inhibition on the
functional phenotype of LPS-stimulated BMDMs and the
human THP1 monocyte cell line. Remarkably, the LPS-
induced increase in expression of inflammatory markers
was attenuated during NOX1 inhibition by GKT771 treat-
ment. Our in vitro results indeed suggest that direct
chemical NOX1 inhibition does not primarily targets hep-
atic tumor cells, as only a slight reduction in metabolic ac-
tivity in human HCC cells and only cytotoxic effects at the
highest concentration in murine HCC cells could be
Fig. 8 NOX1 inhibition attenuates the induction of the pro-inflammatory microenvironment in established HCC in mice. Mice received weekly
DEN (35 mg/kg) injections for 25 or 20 weeks and were administered twice or single daily doses of vehicle/GKT771 via oral gavage in an early or
delayed treatment regimen, respectively. Healthy livers, HCC lesions and surrounding tissue was assessed (a) RT-qPCR analysis to determine the
mRNA expression levels of inflammatory (IL6, TNFα, CCL2, CCR2) and inflammasome (NLRP3, caspase 1, IL1β, iNOS) markers and the immune
suppressive marker PDL1. b Multiplex analysis of IL6, TNFα, CCL2 levels and ROS levels (µM H202 per µg protein). nsnot significant; * p < 0,05; **
p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently
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observed. This might indicate that our observed effects
in vivo might also be mediated by influencing the
polarization of cells characterizing the TME, as also pub-
lished by Liang et al..
Our results of overall safety of NOX1 inhibition on
human HCC cells, the effect of NOX1 inhibition on pro-
inflammatory macrophage polarization and the attenu-
ated development of a pro-tumorigenic environment by
NOX1 inhibition in experimental HCC, suggests this
might be a very promising adjuvant therapeutic strategy
in the treatment of advanced HCC.
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